KCHC Annual Review 2023-24 WEB Singles - Flipbook - Page 58
Notes to the financial statements
4.3. Grant expenditure (continued)
2023/24
2022/23
Unrestricted
Restricted
Total
Total
£’000
£’000
£’000
£’000
-
33
33
26
-
26
Regenerative therapies – paediatric liver
-
275
275
Advancing Parkinson's disease wellness status
-
76
76
Advancing Parkinson's disease wellness 2
-
38
38
Automated detection of spontaneous venous pulsations
with deep learning
62
-
62
Development novel hepatocyte transplantation
49
-
49
Pranic treatment in managing chronic pain
21
-
21
Maximise betablocker benefit cirrhosis
47
-
47
Cardiohelp machine
35
-
35
-
230
230
110
-
110
350
652
1,003
80
-
80
246
10
256
326
10
336
27
-
27
-
-
-
27
0
27
0
1,207
1,358
2,564
1,733
(75)
(25)
(100)
(22)
(75)
(25)
(100)
(22)
1,132
1,332
2,464
2,556
Advancing innovation through research
Regenerative therapies for biliary atresia
Novel electroretinography
3D bioprinting for paediatric liver research
Other grants less than £20,000
403
Supporting staff in delivering the highest possible care
King's Recognition Programme 2023
Other grants less than £20,000
314
Capital projects
Project manager – neuroscience project
Other grants less than £20,000
Total grants awarded
Grants returned, undrawn or written back
Net grant expenditure
An analysis of the 2022/23 grant awards into their
constituent grant components is set out in the 2022/23
Annual Report of the Charity, which is available on the
Charity’s website.
58
S U P P O R T K I N G S .O R G .U K
We invested a total of 442K in new equipment and
technology for the benefit of patients, staff and the
advancement of research.
